These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15663915)

  • 1. ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.
    Funder JW
    Curr Diab Rep; 2005 Feb; 5(1):36-40. PubMed ID: 15663915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
    Sato A; Saruta T; Funder JW
    Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J; Ertl G
    Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aldosterone antagonism in addition to angiotensin-converting enzyme inhibitors in heart failure.
    Bauersachs J; Fraccarollo D
    Minerva Cardioangiol; 2003 Apr; 51(2):155-64. PubMed ID: 12783071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Mineralocorticoid receptor antagonists and therapeutic strategies of cardiovascular damage].
    Verdugo FJ; Montellano FA; Carreño JE; Marusic ET
    Rev Med Chil; 2014 Jan; 142(1):61-71. PubMed ID: 24861116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
    Fügedi K
    Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]).
    Am J Cardiol; 1996 Oct; 78(8):902-7. PubMed ID: 8888663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldosterone antagonists in hypertension and heart failure.
    Mantero F; Lucarelli G
    Ann Endocrinol (Paris); 2000 Feb; 61(1):52-60. PubMed ID: 10790593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure.
    Funder JW
    Expert Opin Investig Drugs; 2003 Dec; 12(12):1963-9. PubMed ID: 14640940
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aldosterone antagonism and congestive heart failure: a new look at an old therapy.
    Thohan V; Torre-Amione G; Koerner MM
    Curr Opin Cardiol; 2004 Jul; 19(4):301-8. PubMed ID: 15218387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aldosterone receptor antagonists for heart failure: current status, future indications.
    Pitt B; Rajagopalan S
    Cleve Clin J Med; 2006 Mar; 73(3):257-60, 264-8. PubMed ID: 16548448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cardiovascular effects of eplerenone, a selective aldosterone-receptor antagonist.
    Davis KL; Nappi JM
    Clin Ther; 2003 Nov; 25(11):2647-68. PubMed ID: 14693297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin blockade or aldosterone blockade as the third neuroendocrine-blocking drug in mild but symptomatic heart failure patients.
    Struthers AD
    Heart; 2006 Dec; 92(12):1728-31. PubMed ID: 16339814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone receptor antagonists and cardiovascular disease: do we need a change of the guard?
    Jewell CW; Watson LE; Mock J; Dostal DE
    Cardiovasc Hematol Agents Med Chem; 2006 Apr; 4(2):129-53. PubMed ID: 16611048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
    Pfeffer MA
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):11-3. PubMed ID: 11504157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure.
    Dieterich HA; Wendt C; Saborowski F
    Fiziol Cheloveka; 2005; 31(6):97-105. PubMed ID: 16366159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.